Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VR040 dose-escalation study for off episodes in advanced idiopathic Parkinson's disease
2006-004582-33Phase 2Completed
- Sponsor
- Vectura
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apomorphine in Parkinson's disease (PD) (2 arms), sponsored by Vectura. Primary endpoint: Primary efficacy endpoint. Started Jan 2012; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2006-004582-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004582-33.